Creso Pharma Ltd (ASX: CPH)

Commercialisation agreement with UK-based Precision Healthcare Ltd: Creso Pharma Ltd (ASX: CPH) has been in the limelight for the past one year given the nutraceutical and medical cannabis company’s efforts in an estimated US$ 385 billion industry, and the recent decision by Australian Federal Government on allowing the export of certain cannabis products to international markets augurs well with the group’s strategy.
 
The group has lately signed a commercialisation agreement with UK-based Precision Healthcare Ltd to market and distribute CPH’s cannaQIX®10 and 50 hemp-based human health nutraceutical products in the UK. The company has planned UK launch of cannaQIX®10 and 50 for Q1 2018. Approvals from Swiss regulatory authorities in terms of a certificate for free sales for the export of the product into the UK from Switzerland, are also now in place.
 
Earlier, the group launched a new joint venture with LGC Capital Ltd and Baltic Beer Company Ltd, namely, CLV Frontier Brands Pty Ltd to develop and globally commercialise a bespoke portfolio of alcoholic and non-alcoholic beverages with cannabis and hemp ingredients.
 

Craft Beer Market (Source: Company Reports)
 
Meanwhile, CPH stock has risen 76.23% in three months as on January 16, 2018; and with the recent UK agreement news, the stock got a boost of 2.3% on January 17, 2018. The statistics and potential seem to pave path for further growth and we give a “Hold” recommendation on the stock at the current price of $1.10

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.